Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease due to elevated triglyceride levels. It has strategic collaboration with Novartis Pharma AG. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKCA
CUSIPN/A
Phone617-207-0202
Debt
Debt-to-Equity RatioN/A
Current Ratio2.55
Quick Ratio2.55
Price-To-Earnings
Trailing P/E Ratio-13.72
Forward P/E Ratio-16.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$55.21 million
Price / Sales47.64
Cash FlowN/A
Price / CashN/A
Book Value$2.70 per share
Price / Book11.38
Profitability
EPS (Most Recent Fiscal Year)($2.24)
Net Income$-109,750,000.00
Net Margins-126.00%
Return on Equity-75.90%
Return on Assets-27.67%
Miscellaneous
Employees100
Outstanding Shares85,590,000
Market Cap$2,589.19
Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions
What is Akcea Therapeutics' stock symbol?
Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."
How were Akcea Therapeutics' earnings last quarter?
Akcea Therapeutics Inc (NASDAQ:AKCA) announced its earnings results on Thursday, May, 3rd. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.07. The business had revenue of $17.11 million for the quarter, compared to analysts' expectations of $12.12 million. Akcea Therapeutics had a negative net margin of 126.00% and a negative return on equity of 75.90%. The business's revenue for the quarter was up 181.0% on a year-over-year basis. View Akcea Therapeutics' Earnings History.
What price target have analysts set for AKCA?
4 brokerages have issued 12-month target prices for Akcea Therapeutics' shares. Their predictions range from $20.00 to $38.00. On average, they anticipate Akcea Therapeutics' share price to reach $29.3333 in the next year. This suggests that the stock has a possible downside of 4.5%. View Analyst Ratings for Akcea Therapeutics.
What is the consensus analysts' recommendation for Akcea Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Akcea Therapeutics' key competitors?
Some companies that are related to Akcea Therapeutics include Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND) and Dr.Reddy's Laboratories (RDY).
Who are Akcea Therapeutics' key executives?
Akcea Therapeutics' management team includes the folowing people:
- Ms. Paula Soteropoulos, CEO & Director (Age 50)
- Mr. Michael F. MacLean, Chief Financial Officer (Age 52)
- Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer, Exec. VP & Head of Regulatory Affairs (Age 67)
- Ms. Sarah Boyce, Pres & Director (Age 46)
- Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 45)
When did Akcea Therapeutics IPO?
(AKCA) raised $125 million in an IPO on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.
Has Akcea Therapeutics been receiving favorable news coverage?
News headlines about AKCA stock have been trending positive on Saturday, Accern reports. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akcea Therapeutics earned a news impact score of 0.26 on Accern's scale. They also assigned news stories about the company an impact score of 44.75 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Akcea Therapeutics' major shareholders?
How do I buy shares of Akcea Therapeutics?
Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akcea Therapeutics' stock price today?
One share of AKCA stock can currently be purchased for approximately $30.73.
How big of a company is Akcea Therapeutics?
Akcea Therapeutics has a market capitalization of $2.59 billion and generates $55.21 million in revenue each year. The company earns $-109,750,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis. Akcea Therapeutics employs 100 workers across the globe.
How can I contact Akcea Therapeutics?
Akcea Therapeutics' mailing address is 55 CAMBRIDGE PARKWAY SUITE 100, CAMBRIDGE MA, 92010. The company can be reached via phone at 617-207-0202 or via email at [email protected]
MarketBeat Community Rating for Akcea Therapeutics (NASDAQ AKCA)
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
